The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Polyphenols in Parkinson’s Disease: A Systematic Review of In Vivo Studies
Open accessAbstract
Parkinson’s disease (PD) is the second most common neurodegenerative disorder. However, therapeutic options treating only its symptoms are very disappointing. Therefore there is an ongoing search for compounds capable of tackling the multi-dimensional features of PD. Recently natural polyphenols have gained great interest as potential therapeutic agents. Herein, we have attempted to summarize results obtained in different animal models demonstrating their neuroprotective effects. The in vivo findings presented below are supported by human subject data and reports regarding the ability of polyphenols to cross the blood-brain barrier. The beneficial effects of polyphenols are demonstrated by the results of behavioral examinations, mainly related to motor and cognitive capabilities, histopathological and immunohistochemical examination concerning the protection of dopaminergic neurons, analyses of dopamine and the concentration of its metabolites, as well as mechanistic studies regarding the modulation of oxidative stress, neuroinflammation, cellular iron management, proteinopathy, and additionally the regulation of signaling pathways. Importantly, data about brain distribution of the metabolic derivatives of the reviewed polyphenols are crucial for the justification of their nutritional intake in neuroprotective intervention, as well as for the identification of potential targets for a novel therapeutic approach to Parkinson’s disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ryu, D., Mouchiroud, L., Andreux, P. A., Katsyuba, E., Moullan, N., Nicolet-dit-Félix, A. A., Williams, E. G., Jha, P., Lo Sasso, G., Huzard, D., et al. (2016) · Nature Medicine · doi:10.1038/nm.4132 · Cited by 1,105 · cited 1×
“Notably, UA has been recently reported to promote mitochondrial health and induce mitophagy in vivo, which has substantial implications for neuroprotection in Parkinson’s disease [142,143].”
BackgroundMitophagy and Alzheimer’s Disease: Cellular and Molecular Mechanisms
Kerr, J. S., Adriaanse, B. A., Greig, N. H., Mattson, M. P., Cader, M. Z., Bohr, V. A., & Fang, E. F. (2017) · Trends in Neurosciences · doi:10.1016/j.tins.2017.01.002 · Cited by 870
Interaction between flavonoids and the blood–brain barrier: in vitro studies
Youdim, K. A., Dobbie, M. S., Kuhnle, G., Proteggente, A. R., Abbott, N. J., & Rice‐Evans, C. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01652.x · Cited by 578
Salazar, J., Mena, N., Hunot, S., Prigent, A., Alvarez-Fischer, D., Arredondo, M., Duyckaerts, C., Sazdovitch, V., Zhao, L., Garrick, L. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804373105 · Cited by 409
Lastres-Becker, I., Molina-Holgado, F., Ramos, J. A., Mechoulam, R., & Fernández-Ruiz, J. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.11.009 · Cited by 407
Lau, Y.-S., Patki, G., Das-Panja, K., Le, W.-D., & Ahmad, S. O. (2011) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2011.07626.x · Cited by 275 · cited 1×
“In another model of PD, MPTP is given with probenecid (p) that blocks the renal clearance of MPTP to prolong its action [89].”
MethodYuan, T., Ma, H., Liu, W., Niesen, D. B., Shah, N., Crews, R., Rose, K. N., Vattem, D. A., & Seeram, N. P. (2016) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5b00260 · Cited by 219 · cited 2×
“The absorbed urolithins undergo subsequent phase I and II metabolism including methylation, glucuronidation, and sulfation [138].”
BackgroundReglodi, D., Renaud, J., Tamas, A., Tizabi, Y., Socías, S. B., Del-Bel, E., & Raisman-Vozari, R. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.10.004 · Cited by 162
Beneficial Effects of Flavonoids Against Parkinson's Disease
Jung, U. J., & Kim, S. R. (2018) · Journal of Medicinal Food · doi:10.1089/jmf.2017.4078 · Cited by 150
Xu, C.-L., Qu, R., Zhang, J., Li, L.-F., & Ma, S.-P. (2013) · Fitoterapia · doi:10.1016/j.fitote.2013.07.009 · Cited by 84 · cited 6×
“The observed effects were accompanied by a decrease in MDA content and an increase in the GSH level, Bcl-2/Bax ratio, and protein expression of brain-derived neurotrophic factor (BDNF) [65].”
BackgroundInfluential
Cited by
Review of Distribution, Extraction Methods, and Health Benefits of Bound Phenolics in Food Plants
Wang, Z., Li, S., Ge, S., & Lin, S. (2020) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.9b06574 · Cited by 269
Diet in Parkinson’s Disease: Critical Role for the Microbiome
Jackson, A., Forsyth, C. B., Shaikh, M., Voigt, R. M., Engen, P. A., Ramirez, V., & Keshavarzian, A. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.01245 · Cited by 145
Nutritional Risk Factors, Microbiota and Parkinson’s Disease: What Is the Current Evidence?
Boulos, C., Yaghi, N., El Hayeck, R., Heraoui, G. N., & Fakhoury-Sayegh, N. (2019) · Nutrients · doi:10.3390/nu11081896 · Cited by 109
“These results were more confirmed by in vitro studies and experimental animal models where tea drinking was identified to reduce peroxidation and enhance antioxidative enzyme activity [106].”
BackgroundResultAshraf, M. V., Khan, S., Misri, S., Gaira, K. S., Rawat, S., Rawat, B., Khan, M. A. H., Shah, A. A., Asgher, M., & Ahmad, S. (2024) · Pharmaceuticals · doi:10.3390/ph17080975 · Cited by 102
Henríquez, G., Gomez, A., Guerrero, E., & Narayan, M. (2020) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.0c00381 · Cited by 83
Urolithins: Potential Biomarkers of Gut Dysbiosis and Disease Stage in Parkinson’s Patients
Romo-Vaquero, M., Fernández-Villalba, E., Gil-Martinez, A.-L., Cuenca-Bermejo, L., Espín, J. C., Herrero, M. T., & Selma, M. V. (2022) · Food & Function · doi:10.1039/d2fo00552b · Cited by 54
Metadata
- Authors
- Kujawska, M., & Jodynis-Liebert, J.
- Venue
- Nutrients
- Publisher
- MDPI AG
- Published
- 2018-05-19
- Volume
- 10
- Issue
- 5
- Pages
- 642
- ISSN
- 2072-6643 (ISSN-L)
- OpenAlex
- W2804325486
- Cited by
- 175
- References
- 10
- FWCI
- 3.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.